News for AnaptysBio, Inc. (0HFQ.L)

An upcoming conference call with the management of AnaptysBio, Inc. (ANAB) is scheduled for June 9 at 1:30 pm. This event will be facilitated by JPMorgan. Inves

AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight its potential. Click for my ANAB update.

AnaptysBio (ANAB) recently conducted a webcast to share encouraging findings from its Phase 2b trial of rosnilimab in treating rheumatoid arthritis. The company

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday. The Dow traded up 0.09% to 42,558....

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

AnaptysBio (ANAB) has announced positive results from its Phase 2b clinical trial of rosnilimab, a drug targeting PD-1+ T cells, in patients with moderate-to-se

AnaptysBio's (ANAB) rosnilimab shows promising results in Phase 2b rheumatoid arthritis trial, achieving 69% low disease activity at Week 14. Favorable

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday. Shares of HEICO Corporation HEI rose sharply during Wednesday's ses...

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. ( ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology thera

AnaptysBio (ANAB) to present updated Phase 2b RENOIR trial data for rosnilimab on June 3, 2025. Key experts involved include Dr. Paul Emery and Dr. Jona

BlackRock highlighted that the trade conflict between the US and China continues to cause major economic disruptions.

Revenue: $27.8 million, significantly surpassing the estimated $15.27 million for the quarter.Net Loss: $39.3 million, with a net loss per share of $1.28, slig

On April 23, 2025, Sanofi (Trades, Portfolio), a prominent player in the investment landscape, executed a significant transaction by acquiring 8,345,387 shares

In a recent update, Guggenheim analyst Yatin Suneja has maintained a "Buy" rating for AnaptysBio (ANAB). This decision underscores continued confidence in the c

VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. ( CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CC

Guggenheim has adjusted its price target for AnaptysBio (ANAB), raising it from $52 to $54. The firm maintains a Buy rating on the company's shares. This decisi

AnaptysBio, Inc. (ANAB) reported a substantial increase in first-quarter revenue, reaching $27.77 million, significantly surpassing the consensus estimate of $1

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated

AnaptysBio (ANAB) delivered earnings and revenue surprises of 1.54% and 52.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?